Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TKPHF) EBT (2017 - 2025)

Historic EBT for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to $869.7 million.

  • Takeda Pharmaceutical's EBT fell 1535.43% to $869.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.3 billion, marking a year-over-year increase of 4869.55%. This contributed to the annual value of $1.1 billion for FY2025, which is 21399.29% up from last year.
  • Per Takeda Pharmaceutical's latest filing, its EBT stood at $869.7 million for Q4 2025, which was down 1535.43% from $6.1 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's EBT ranged from a high of $6.1 billion in Q3 2025 and a low of -$320.7 million during Q1 2024
  • Moreover, its 5-year median value for EBT was $1.2 billion (2022), whereas its average is $1.7 billion.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 135306.77% in 2021, then plummeted by 12727.77% in 2024.
  • Takeda Pharmaceutical's EBT (Quarter) stood at $635.1 million in 2021, then increased by 19.42% to $758.5 million in 2022, then soared by 87.22% to $1.4 billion in 2023, then decreased by 27.65% to $1.0 billion in 2024, then decreased by 15.35% to $869.7 million in 2025.
  • Its EBT stands at $869.7 million for Q4 2025, versus $6.1 billion for Q3 2025 and $2.0 billion for Q2 2025.